Oragenics (NYSEAMERICAN:OGEN – Get Free Report) issued its earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, FiscalAI reports.
Oragenics Price Performance
NYSEAMERICAN OGEN traded up $0.01 during trading hours on Friday, hitting $0.54. The company had a trading volume of 2,280 shares, compared to its average volume of 237,651. Oragenics has a fifty-two week low of $0.48 and a fifty-two week high of $1.45. The company has a market capitalization of $2.42 million, a price-to-earnings ratio of -0.03 and a beta of 1.24. The firm’s 50 day moving average is $0.56 and its 200 day moving average is $0.64.
Institutional Investors Weigh In On Oragenics
Large investors have recently modified their holdings of the stock. DRW Securities LLC raised its holdings in shares of Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after buying an additional 50,900 shares during the period. XTX Topco Ltd purchased a new position in Oragenics in the 4th quarter worth approximately $26,000. Finally, Bank of America Corp DE grew its position in Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after acquiring an additional 15,338 shares in the last quarter. Institutional investors and hedge funds own 18.71% of the company’s stock.
About Oragenics
Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.
The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.
Read More
- Five stocks we like better than Oragenics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
